CTNM: Contineum Therapeutics Inc. Class A Common Stock Stocks News on May 20, 2025

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

CTNM

Business Wire

4 days ago

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

CTNM

Business Wire

5 days ago

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

CTNM

Business Wire

21 days ago

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

CTNM

Simply Wall St.

a month ago

We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

CTNM

Business Wire

2 months ago

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

CTNM

Simply Wall St.

2 months ago

Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

CTNM

Business Wire

2 months ago

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

CTNM

Business Wire

2 months ago

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

CTNM

Business Wire

3 months ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

CTNM

Business Wire

3 months ago

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

CTNM

Business Wire

4 months ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

CTNM

GlobeNewswire

4 months ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

CTNM

Business Wire

5 months ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

CTNM

Business Wire

6 months ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

CTNM

Business Wire

6 months ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

CTNM

Simply Wall St.

6 months ago

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Contineum Therapeutics to Attend Upcoming Investor Conferences

CTNM

Business Wire

6 months ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CTNM

Business Wire

6 months ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CTNM

Simply Wall St.

8 months ago

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

CTNM

Business Wire

9 months ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

CTNM

Business Wire

9 months ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

CTNM

Business Wire

10 months ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

CTNM

Business Wire

a year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

CTNM

Business Wire

a year ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

CTNM

Business Wire

a year ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

CTNM

Business Wire

a year ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

CTNM

Business Wire

a year ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

CTNM

GlobeNewswire

a year ago

Latest Contineum Therapeutics Inc. Class A Common Stock (CTNM) News on May 20, 2025

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Announces Pricing of Initial Public Offering

Share on Social Networks: